Safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671 in healthy participants and patients with hyperuricemia and gout: a proof-of-concept study
Background This proof-of-concept study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671, a novel URAT1 inhibitor, in healthy participants and in patients with hyperuricemia and gout. Methods This single-center, randomized, double-blind, place…